SFL's Managing Director Invited to Speak at DIA 49th Annual Meeting in Boston
06/07/2013

SFL to speak at the session “Co-development of Targeted Therapies and Companion Diagnostics: Identifying Regulatory Strategies to Overcome Challenges”

Online PR News – 07-June-2013 – Basel/Switzerland – SFL is pleased to announce that Shayesteh FĂĽrst-Ladani, Managing Director of the company, has been invited as a panel member and give a presentation at the DIA 2012 49th Annual Meeting to be held June 23-27 at the Boston Convention and Exhibition Center in Boston, US.

Ms. Fürst-Ladani has been invited to speak at the session “Co-development of Targeted Therapies and Companion Diagnostics: Identifying Regulatory Strategies to Overcome Challenges” on Tuesday, June 25 at 1:45 pm–3:15 pm. In her presentation entitled “European regulatory oversight of companion diagnostics”, Shayesteh will provide an overview of the latest developments of the European legislation on companion diagnostics (CDx) and explain potential implications for drug and IVD companies.

“This session will assist manufacturers in understanding the regulatory changes taking place for CDxs,” commented Shayesteh. “It will enable companies to learn about the practical implications of the new regulatory framework and understand what will be expected of them in the future in terms of meeting required standards.

Shayesteh is the Managing Director and founder of SFL. She has comprehensive experience in formulating global regulatory strategies and provides support for the development of drugs, orphan drugs, drug and device combination products, borderline products, medical devices, in vitro diagnostics and advanced therapy medicinal products.

Shayesteh is Chair of the Combination Products Topic Group at EuropaBio. She has been member of the Program Committee of DIA EuroMeeting for 2011, 2012, 2013 and 2014 leading the Theme Drugs, Devices, In Vitro Diagnostics and their Combinations. In 2012 she received the Open University Business School’s Alumni Award Outstanding Contribution to an Organization.

About SFL Regulatory Affairs & Scientific Communication Ltd
SFL is dedicated to a holistic approach to lifecycle management of healthcare products with expertise in Regulatory Affairs, Public Affairs, Legal Services and Medical Communication. SFL provides a personalized and integral oversight package for products from the bench to the marketplace at one consultancy. SFL provides clients with expert guidance on ethical aspects of lifecycle management issues, with consideration of the appropriate values, norms and principles ensuring consistent and coherent decisions are made. SFL also runs specialized training courses based on the team’s cross-functional expertise.

visit our website